SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Syringe drawing from a series of vials/i
Business
Bavarian Nordic Puts Kibosh on Cancer Vaccine, Focuses on Infectious Diseases
Danish biotech Bavarian Nordic announced Wednesday it is discontinuing its immuno-oncology program and will focus its R&D efforts on infectious diseases.
February 21, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie CEO Gonzalez to Retire July 1 After More Than a Decade at Helm
President and COO Robert Michael will take over Richard Gonzalez’s CEO duties, AbbVie announced Tuesday. Gonzalez will become executive chairman of the board of directors.
February 21, 2024
 · 
2 min read
 · 
Tyler Patchen
Drug Delivery
Iovance wins with Amtagvi and the ADC train chugs on
This week Lori, Greg and Tyler discuss the ⁠Accelerated Approval of Amtagvi⁠, the first one-time cell therapy for solid tumors and the first TIL therapy; the ⁠FTC and HHS probe⁠ into generic drug shortages and some recent ADC-focused raises from ⁠ProfoundBio⁠ and ⁠Firefly Bio⁠.
February 20, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: FDA sign at Washington D.C. headquarters
Drug Development
FDA Puts Clinical Hold on RAPT Therapeutics’ Lead Candidate in Two Trials
The regulator has placed a clinical hold on RAPT Therapeutics’ drug zelnecirnon, which was being investigated in atopic dermatitis and asthma, after a patient experienced liver failure.
February 20, 2024
 · 
2 min read
 · 
Tyler Patchen
External view of AstraZeneca's headquarters building in Silicon Valley
Drug Development
AstraZeneca Looks to Differentiate in Kidney Disease Space Despite Setback: GlobalData
While AstraZeneca discontinued its Phase IIb trial for tozorakimab, the pharma’s zibotentan—if approved—could be “an optimal treatment of choice” for patients with diabetic kidney disease, finds a new report from GlobalData.
February 20, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer office at its South San Francisco
Policy
Pfizer’s Ulcerative Colitis Drug Velsipity Approved by European Regulators
The European Commission granted marketing authorization in the EU to treat patients 16 years of age and older with moderately to severely active ulcerative colitis.
February 20, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Exterior of an FDA building
Policy
FDA Accepts BLA for AstraZeneca, Daiichi Sankyo’s ADC for NSCLC
The companies’ Biologics License Application for antibody-drug conjugate datopotamab deruxtecan has been accepted by the FDA for locally advanced or metastatic nonsquamous non-small cell lung cancer.
February 19, 2024
 · 
2 min read
 · 
Tyler Patchen
Policy
Alvotech Reaches Settlement with J&J Over Stelara Biosimilar
The Icelandic biotech Thursday said that it has settled its grievances with Johnson & Johnson regarding its Stelara biosimilar in markets with regulatory approval.
February 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage at its world headquarters in New York
Policy
Pfizer Settles Lipitor Antitrust Suit for $93M, Ends Decade-Long Court Battle
Pfizer plans to settle a lawsuit filed 12 years ago by distributors of Lipitor for $93 million. The pharma giant was accused of colluding with Ranbaxy Laboratories to delay generic versions of the drug.
February 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Alnylam headquarters in Massachusetts/iS
Drug Development
Alnylam Makes Endpoints Changes to ATTR Study for Amvuttra
Alnylam Pharmaceuticals is modifying the primary and secondary endpoints of the Helios-B Phase III trial investigating its next-generation RNA interference therapy in patients with ATTR amyloidosis with cardiomyopathy.
February 16, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Sarepta sign on a brick building/courtes
Policy
FDA Accepts Sarepta’s Efficacy Supplement Seeking to Expand Elevidys Indication
The regulator has granted a priority review of the efficacy supplement for Sarepta Therapeutics’ gene therapy Elevidys with a target decision date of June 21, 2024.
February 16, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: 3D illustration of antibody-drug conjugates carrying toxic payloads
Business
ADC-Focused Firefly Bio Emerges from Stealth with $94M Series A
Co-founded by Nobel Prize winner Carolyn Bertozzi, Firefly’s venture funding is backed by Eli Lilly and Versant Ventures, among others, to support its novel platform for merging antibody-drug conjugates with protein degraders.
February 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Flag on Federal Trade Commission buildin
Policy
FTC and HHS Launch Probe of Ongoing Generic Drug Shortages
The Federal Trade Commission and Department of Health and Human Services on Wednesday said they are investigating group purchasing organizations and drug wholesalers’ possible involvement.
February 14, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: European flags flap in the wind outside
European-Based VC Earlybird Health Closes $186M Fund
The venture capital fund will finance companies in Europe who are in the early stages of development with the goal of advancing them to regulatory approval and commercialization.
February 14, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3D rendering of antibody-drug conjugate/
BioForest
ADC-Focused ProfoundBio Raises $112M in Oversubscribed Series B
The latest round of funding for Seattle-based ProfoundBio will go towards advancing its one preclinical and three clinical antibody-drug conjugate candidates.
February 14, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More